Cholesterol · The Complete Deep Dive

For 70 years we have been fighting the firefighter. Not the fire.

Cholesterol is not the perpetrator. It is the repair crew, trying to make good on what sugar, stress, seed oils, and toxins have done to your endothelium. This is a deep dive through 100 years of science, with more than 25 verified studies and my personal story. With substantially more science than in any GP practice.

My paternal grandfather died before I was born. Of a heart attack. My maternal grandfather as well. Both. Both supposedly because they had eaten too much meat and too much fat. That was the family truth. And that is exactly why, at 19, in medical school, I started believing what was being told to us up at the front of the lecture hall: high cholesterol? Less butter. Fewer eggs. Less meat. So that you live long enough for your grandchildren to know you. That is how I protected myself. I thought.

Where I started

In the lecture hall, without a single clean piece of evidence, we were told to recommend that patients eat fewer eggs, less butter, and less meat to protect them from heart attacks.

That is not differentiated medicine. That is the repetition of a mistake we have been making since the 1950s.

I am not fighting the cholesterol value. I am fighting the blanket generalization. If your GP measures your value and recommends statins without knowing your subclasses, your Apo-B, your Lp(a), your insulin, your HbA1c, and your triglycerides, that is medicine from 1955.

What you are reading now is the answer to a question I could not get out of my head after three years on Paleo: How can it be that what healed my whole body is supposed to destroy my heart?

My story · The whole arc

Both grandfathers. Both heart attack. Both before I was born.

My paternal grandfather died before my father became a father. My maternal grandfather likewise. Both died before I was born. Both of a heart attack. In my family this counted as proof: we eat too much meat, we eat too much fat, we die young.

I did not want to repeat that. I wanted to grow old. I wanted my grandchildren to know me. So I held to the recommendation that medical school and family history together pressed upon me: less meat, fewer eggs, less butter.

Three years vegan. I was okay. But not good.

I was vegan for three years. I lived it with full conviction. After two years I developed sleep problems. Irritability. A sudden intolerance of legumes, then of gluten. I compensated for years: 30 minutes of breathwork in the morning, 30 minutes of HIIT, then ice baths. With that much discipline, anything works, for a while.

Then Paleo. No grains, no legumes, no dairy, no nightshades.

What was left: meat, eggs, vegetables, fruit. I deliberately left out fish because of the heavy-metal burden, especially methylmercury. About 250 grams of meat and at least five eggs a day. At first I thought it was crazy.

After three months I felt better than ever before. It kept going. Better and better, even though I had not felt bad before. With Paleo I did not have to compensate anymore. Twice the energy, and balanced.

After nine months the white spots on my fingernails, which I had carried my whole life, were gone. My beard grew in properly for the first time in my life. I had thought I just did not have the “beard genotype.” Wrong. My metabolism had simply received building blocks it had not had before. My relationship to stress changed. The textures in my body changed.

After a year I could tolerate legumes and gluten again.

At 28 I felt fitter than at 18. And at 18 I had thought I was indestructible. Right at that moment came the question that would not let me go: can something that heals my whole body destroy my heart? It makes no sense that my whole body heals and then I die earlier of a heart attack. Something is missing in the story the university told me.

That question pushed me to systematically work through every relevant cholesterol study between 1913 and 2020. What I found is this article. I felt deceived. I was angry. We keep making the same mistakes in history.

Part 1 · What cholesterol does in the body

If your body stopped making cholesterol tomorrow, you would be dead the day after.

Before we talk about risk, we have to talk about function. Because function has almost dropped out of every consultation.

Cholesterol is the building block of your cell membrane. Every single cell in you, from a skin cell to a neuron in the frontal cortex, has a membrane that without cholesterol would collapse like a wall without mortar. Cholesterol regulates how fluid or firm that membrane is. Too little of it and signals are no longer cleanly passed on.

Cholesterol is the precursor of every steroid hormone. Testosterone, estrogen, progesterone, cortisol, aldosterone, DHEA. Everything you need to get out of bed in the morning, fall in love, become pregnant, or survive a conflict, begins as a cholesterol molecule in a gland.

Cholesterol is the precursor of vitamin D. The 7-dehydrocholesterol in your skin is converted by sunlight to vitamin D3, which is then activated in liver and kidney. No cholesterol, no vitamin D.

Cholesterol is the basis of your bile acids. Without bile, no fat digestion, no fat-soluble vitamins A, D, E, K.

Cholesterol is directly involved in the repair mechanism of your endothelium. Where your vessel wall develops microscopic tears, it is the cholesterol in LDL particles that seals the wound. We will return to that in detail later.

The metabolism in numbers

Cholesterol balance per day
200 to 500 mg
from your food
10,000 mg
body pool
500 to 1,000 mg
own synthesis in the liver
More than 95 percent of your cholesterol is built by your body itself. What you eat is only a small part. If you eat less, the liver builds more. If you eat more, it builds less. It self-regulates.

Let that sink in for a moment. The body pool holds about 10 grams of cholesterol. Only about 5 percent comes from food, the rest is built in the liver itself, mainly via the enzyme HMG-CoA reductase. That is exactly the enzyme statins inhibit.

The consequence: if you eat three eggs today, the liver compensates. It builds less. If you skip the eggs, it builds more. This has been experimentally documented for decades. The recommendation “eat fewer eggs so your cholesterol drops” physiologically does not work.

Reframe #1

Cholesterol is not something we eat that harms us. Cholesterol is something we build ourselves, because we need it to survive. When your value is high, the good physician asks: why is your body building so much of it right now? Not: how do we lower it?

And now you know why the old recommendation “eat less butter” biologically makes no sense.

Part 2 · How cholesterol became the villain

1955, Eisenhower collapses. Ancel Keys delivers the explanation. A whole world believes it.

For you to understand where the myth comes from, we have to go back 70 years. The truth is: the thesis “saturated fats cause heart attacks” was not born from a clean study. It was born from a press conference after a heart attack.

The timeline of cholesterol doctrine
1913

Anitschkow feeds rabbits cholesterol and observes plaques. Rabbits are obligate herbivores. The result is not transferable to humans. The study still becomes the birth certificate of the cholesterol theory.

1950

John Gofman separates lipoproteins by ultracentrifugation and discovers LDL and HDL. Differentiation begins, but does not reach primary care for decades.

1955

Eisenhower suffers a severe heart attack. His personal physician Paul Dudley White goes public, issues dietary recommendations. Cholesterol becomes politics.

1958

Ancel Keys starts the Seven Countries Study. He had data from 22 countries. Sixteen countries whose data did not fit were left out. What remained was a beautiful line between saturated fats and cardiac death.

1961

The American Heart Association officially recommends, for the first time, replacing saturated fats with polyunsaturated vegetable oils. Worldwide seed oil consumption explodes.

1968

Start of the Minnesota Coronary Experiment. The largest randomized diet experiment in history on the cholesterol hypothesis. The data disappear into a basement for 40 years.

1988

Krauss and Austin describe the LDL subclasses. From now on it is clear: LDL is not equal to LDL. This insight needs another 20 years to reach guidelines, and to this day has not arrived in GP practice.

2013

Christopher Ramsden digs out the original Sydney Diet Heart data. In the linoleic-acid group there were more deaths. Published in the BMJ.

2016

Ramsden digs out the Minnesota data. Per 30 mg/dL of cholesterol lowering, 22 percent more deaths. Published in the BMJ.

What follows from this story: the recommendation “less saturated fat” was not born from more knowledge, but from a political moment. And in parallel with the recommendation came a second phenomenon, almost never discussed in practice.

The great fat switch and what came after

After Eisenhower, the United States, then Europe, in the broad population switched from animal fat to industrial seed oils. Corn, soy, safflower, sunflower, canola. Before 1900 the ratio of omega-6 to omega-3 in the Western diet was about 1 to 1. Today it averages around 15 to 1, in the US sometimes 25 to 1.

What has happened since? Heart attacks rose instead of falling. They became younger. Suddenly sons were dying of heart attacks at the same age as their fathers, often in the same generation. Obesity, type 2 diabetes, autoimmune disease, dementia, all multiplied. The only major variables newly added to the menu in this period: industrial seed oils and refined carbohydrates.

We told people to replace butter with margarine to protect their hearts. The exact opposite happened. There are solid data for this today.
Part 3 · Cholesterol as repair crew

LDL is in plaque because plaque is a repair. Not because LDL attacks the wall.

Picture the endothelium of your vessels as a smooth, paper-thin foil. Three cells thick. It produces the nitric oxide that relaxes your vessels. It prevents blood from clotting where it should not. It regulates what comes in and what goes out.

When this foil tears, microscopically, several times every day, the body has to apply something to seal the wound. That is precisely a central task of LDL. It transports cholesterol to the damaged sites. Cholesterol is built in there. The wound closes. Over time, plaque forms.

Plaque, then, is not the beginning. Plaque is the answer.

Reframe #2

If you lower cholesterol without calming the endothelium, your body has less material to repair the daily tears. You are fighting the painter, not the hammer that is smashing the wall. If we fight cholesterol without asking why the damage to the wall is happening, we are practicing symptomatic medicine.

What are the hammers? The hammers are what wounds your endothelium every day. This is exactly the point at which discussion in German practices often ends. It should begin here.

What really destroys your endothelium
  • Hyperglycemia and insulin resistance. High blood sugar spikes generate advanced glycation end products (AGEs) and oxidative stress. This is the most common driver in modern everyday life.
  • Linoleic acid from industrial seed oils. Sunflower, safflower, soy, corn, canola. It oxidizes easily. The oxidized metabolites (OXLAMs) are found enriched in plaques. They turn harmless LDL into aggressive LDL.
  • Chronic stress and constant sympathetic activation. Elevated heart rate, elevated blood pressure, chronically elevated cortisol. This stresses the endothelium mechanically and biochemically.
  • Alcohol, regularly. A direct endothelial toxin that promotes lipid peroxidation and insulin resistance.
  • Smoking. Direct oxidative stress with every inhalation.
  • Heavy metals and mycotoxins. Mercury, cadmium, mold toxins. All are documented endothelial toxins.
  • Sleep deprivation. Worsens insulin sensitivity, raises cortisol, reduces HRV.
  • Lack of movement. Reduces NO production in the endothelium, promotes insulin resistance.
Mechanism reviewDiNicolantonio & O’Keefe, 2018, Open Heart. The oxidized linoleic acid hypothesis

Published in the peer-reviewed BMJ journal Open Heart. The authors lay out the mechanisms showing that oxidized linoleic acid metabolites are markedly enriched in atherosclerotic plaques. They argue that the driver of atherosclerosis is not cholesterol itself but the oxidative modification linoleic acid from seed oils causes on the LDL particle.

Consequence: linoleic acid reduction is a plausible point of leverage that has so far played hardly any role in German guidelines.

DiNicolantonio JJ, O’Keefe JH. Omega-6 vegetable oils as a driver of coronary heart disease: the oxidized linoleic acid hypothesis. Open Heart. 2018;5(2):e000898. doi.org/10.1136/openhrt-2018-000898

Human study, 8 weeksReaven et al., 1993, J Clin Invest. Olive oil vs. linoleic acid

Subjects with mildly elevated cholesterol received eight weeks of diets rich in oleic acid (olive oil) or linoleic acid (seed oil). The LDL of the olive oil group was significantly more resistant to oxidation. The 18:2 linoleic acid content in LDL correlated directly with the tendency to oxidize. The authors recommended in 1993 to use olive oil instead of PUFAs. It did not become German guidance.

Reaven P, Parthasarathy S, Grasse BJ, et al. Effects of Oleate-Rich and Linoleate-Rich Diets on the Susceptibility of Low Density Lipoprotein to Oxidative Modification. J Clin Invest. 1993;91(2):668–676. doi.org/10.1172/JCI116247

This is the decisive point: If we lower cholesterol without addressing these drivers, we are practicing symptomatic medicine. We are fighting the reaction, not the cause. Just as if one were to arrest the firefighters instead of putting out the fire.

Part 4 · The differentiation that changes everything

First total cholesterol. Then HDL and LDL. Then subclasses. Today Apo-B and Lp(a). In German GP practices we are often still in the 1960s.

The history of cholesterol science is a history of progressive differentiation. Each step has weakened or even reversed the previous statement. You have to understand this, otherwise you cannot understand the dispute.

Stage one: total cholesterol

At first only one value could be measured. There was a rough correlation between high total cholesterol and heart attack rate. That was the state in 1950. From this came the recommendation “lower your cholesterol.” Plausible, but too sweeping.

Stage two: HDL and LDL

With John Gofman and ultracentrifugation it became clear: there are at least two main classes. HDL has been considered “good” ever since, LDL “bad.” This is already a simplification. But at least it was clear: high total cholesterol with high HDL means something different from high total cholesterol with low HDL.

OverviewCastelli, 1996, Atherosclerosis. What the Framingham data really show

William P. Castelli was one of the central figures of the Framingham Heart Study. In this overview he makes very clear: there are over 200 known cardiovascular risk factors. The most important are lipid subclasses, triglycerides, blood pressure, and smoking, not total cholesterol alone. Castelli explicitly writes that more than 15 different cholesterol-containing lipoproteins exist and four different triglyceride-rich particles, some of them strongly atherogenic.

He recommends two simple tests: the ratio of total cholesterol to HDL and triglycerides. Only then can it be decided whether LDL, HDL, or triglyceride-rich particles are the risk. German GP practice in 2025 has not caught up with this in breadth.

Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis. 1996;124 Suppl:S1–9. doi.org/10.1016/0021-9150(96)05851-0

The most important takeaway from Framingham: The higher your HDL, the higher your LDL may go before the risk even rises. Someone with an HDL of 75 mg/dL can have an LDL of 160 without being endangered. Someone with an HDL of 30 and an LDL of 130 is in a completely different cardiological world. We have known this for decades. And still in German GP practice often only the total cholesterol is reported and warned about.

Stage three: LDL has subclasses

Here comes the insight that turns everything upside down. LDL is not a homogeneous substance class. There are at least three measurable subclasses, which differ massively in size, density, and risk.

Phenotype A
Large LDL (LD-LDL)

Large, light, “fluffy” LDL particles. They release cholesterol cleanly to cells. Low oxidation susceptibility, low entry rate into the vessel wall. Little atherogenic.

Transition
Medium LDL (MD-LDL)

Medium-sized. Atherogenic risk partly raised, especially in combination with insulin resistance and inflammation. On the spectrum between truly harmless and truly dangerous.

Phenotype B
Small dense LDL (SD-LDL)

Small, dense, oxidation-prone. Easily penetrates the vessel wall. Stays there long. Strongly atherogenic. Rises under refined carbohydrates, insulin resistance, stress, and especially industrial seed oils.

ReviewVekic et al., 2022, Medicina. Small, dense LDL as an independent risk factor

This systematic overview summarizes: small dense LDL has a higher entry rate into the vessel wall, a longer dwell time there, a markedly higher tendency to oxidize, and a reduced affinity for the LDL receptor. The result is enrichment in the subendothelium and accelerated plaque formation.

The critical consequence for your GP practice: not every high LDL is dangerous. High LDL with a lot of phenotype A means something completely different from high LDL with a lot of phenotype B. Whoever does not separate these is treating blindly.

Vekic J, Zeljkovic A, Cicero AFG, et al. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. Medicina (Kaunas). 2022;58(2):299. doi.org/10.3390/medicina58020299

Mechanism reviewGriffin, 1999, Proceedings of the Nutrition Society

More than 25 years ago, the lipid researcher Bruce Griffin wrote very clearly: “Elevated serum cholesterol does not adequately explain the increased coronary heart disease risk within the population.” The atherogenic potential of LDL does not come from its cholesterol content but from the number of small, dense LDL particles.

This statement is from 1999. It has not arrived in German GP practices in 2025.

Griffin BA. Lipoprotein Atherogenicity: An Overview of Current Mechanisms. Proc Nutr Soc. 1999;58(1):163–169. doi.org/10.1079/pns19990022

What drives SD-LDL up?

The most important answer: not the steak. Fast carbohydrates. Bread, juice, sugar, refined starches. They raise triglycerides, and triglycerides raise the share of SD-LDL. Even a low-fat diet that lowers total LDL can raise the SD-LDL share, because it pushes triglycerides up.

ReviewHirano, 2018. Insulin resistance generates the atherogenic lipid profile

This review article shows very clearly: insulin resistance, the precursor of type 2 diabetes, is the driver behind the classic “diabetic fat pattern.” High triglycerides, low HDL, lots of SD-LDL. Exactly the profile found in most Western heart attacks.

Consequence: when the GP looks at your cholesterol without knowing your insulin, they are looking only at the tip of the iceberg.

Hirano T. Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb. 2018;25(9):771–782. doi.org/10.5551/jat.RV17023

Stage four: Apo-B and Lp(a)

Apo-B stands for apolipoprotein B. Simplified: every atherogenic particle, that is LDL, SD-LDL, VLDL, IDL, Lp(a), carries exactly one Apo-B protein on its surface. When you measure Apo-B, you are counting the number of particles that can really do damage. Not the volume of cholesterol they transport.

Two people can have the same LDL value. One has 800 large, fluffy particles. The other has 1,500 small, dense ones. Same cholesterol value. Different risk, often by a factor of two or three. Apo-B distinguishes this. Total cholesterol does not.

ReviewSniderman, 2013. Apo-B is superior to cholesterol markers

Allan Sniderman, one of the patriarchs of lipoprotein research, shows in this meta-analysis of prospective studies that Apo-B outperforms both non-HDL cholesterol and LDL cholesterol as a risk predictor. Three separate discordance analyses confirm: when Apo-B and LDL-C do not agree, Apo-B is the better predictor. His conclusion: epidemiology without physiology is like firing without aiming.

Sniderman A, Kwiterovich PO. Update on the detection and treatment of atherogenic low-density lipoproteins. Curr Opin Endocrinol Diabetes Obes. 2013;20(2):140–147. doi.org/10.1097/MED.0b013e32835ed9cb

Lp(a), pronounced “lipoprotein little a,” is a genetically determined, very atherogenic particle. Anyone with high Lp(a) has a markedly increased risk for early heart attacks, independent of everything else you do. Lp(a) is measured once in a lifetime, because it is genetic. And still in German GP practice it is almost never run.

ReviewKamstrup, 2021, Clinical Chemistry. Lp(a) is its own causal risk factor

Pia Kamstrup of the Copenhagen General Population Study summarizes: Mendelian randomization and large cohorts show a causal contribution of Lp(a) to coronary heart disease, peripheral artery disease, and aortic valve stenosis. High Lp(a) values predict a two- to threefold increased risk, independent of everything else. 10 to 20 percent of the population have high values. Most do not know it.

Kamstrup PR. Lipoprotein(a) and Cardiovascular Disease. Clin Chem. 2021;67(1):154–166. doi.org/10.1093/clinchem/hvaa247

GuidelineESC/EAS Guidelines, 2019. Apo-B and Lp(a) belong in the risk profile

The European cardiologists in the 2019 guidelines recognize Apo-B as an equivalent or better marker than LDL, especially in diabetes, obesity, insulin resistance, or high triglycerides. Lp(a) is included as an independent risk factor. That is the official European recommendation.

And yet routine in many German GP practices still reduces to total and LDL cholesterol. That is not wrong, it is just five values short.

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188. doi.org/10.1093/eurheartj/ehz455

Reframe #3

If your GP calls your cholesterol “too high,” and the next question is not “what are your HDL, your Apo-B, your Lp(a), your triglycerides, your HbA1c, and your fasting insulin?”, then they have not updated the discussion in decades.

Part 5 · The two studies everyone should know

Sydney Diet Heart and Minnesota Coronary Experiment. Cholesterol lowered. More deaths.

The most important randomized controlled trials ever conducted on the cholesterol hypothesis lay in drawers for decades. Only Christopher Ramsden of the US National Institutes of Health dug them out again.

RCT, n=458Sydney Diet Heart Study (Ramsden 2013)

458 men, all after a heart attack. One group replaces saturated animal fats with safflower oil and margarine. The other group stays with normal diet. Follow-up over several years.

Result on reanalysis: in the linoleic acid group significantly more people die. 17.6 percent versus 11.8 percent all-cause mortality. Hazard ratio 1.62. From cardiovascular disease 17.2 to 11.0 percent. Statistically significant.

Ramsden CE, Zamora D, Leelarthaepin B, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death. BMJ. 2013;346:e8707. doi.org/10.1136/bmj.e8707

RCT, n=9,423Minnesota Coronary Experiment (Ramsden 2016)

A double-blind randomized study in 9,423 people. Test: if saturated fat is replaced with corn oil, does cholesterol drop? Does it protect from cardiac death?

Result: cholesterol fell by 13.8 percent. Per 30 mg/dL of cholesterol lowering, however, mortality risk rose by 22 percent. Statistically significant. There was no protection from heart attacks. The original data sat unused for 40 years.

Ramsden CE, Zamora D, Majchrzak-Hong S, et al. Re-evaluation of the traditional diet-heart hypothesis: Minnesota Coronary Experiment. BMJ. 2016;353:i1246. doi.org/10.1136/bmj.i1246

RCT, n=26 (crossover)Berry et al., 1991. Jerusalem Nutrition Study

26 yeshiva students received in crossover design twelve weeks each of a diet rich in monounsaturated fats (olive oil) or polyunsaturated fats (typical seed oils). Both lowered LDL. PUFA more strongly (16 percent). MUFA less (10 percent).

The crucial observation: the LDL of the PUFA group was significantly more oxidation-prone, measured by TBARS values. More LDL lowering, but more atherogenic LDL. Exactly the mechanism behind the Sydney and Minnesota findings.

Berry EM, Eisenberg S, Haratz D, et al. Effects of Diets Rich in Monounsaturated Fatty Acids: the Jerusalem Nutrition Study. Am J Clin Nutr. 1991;53(4):899–907. doi.org/10.1093/ajcn/53.4.899

Cholesterol lowered. More deaths. Cholesterol lowered. LDL more atherogenic. That is the state of the highest-quality randomized trials ever done on the cholesterol hypothesis.
Part 6 · The fatal logical leap

“Vegan lowers LDL, therefore vegan protects from heart attack.” This bridge must not be built.

If I had to take one single thing from 100 years of cholesterol science, it would be this: there is a logical leap that has stood in German textbooks for decades and is not tenable as such.

Step one: LDL correlates with cardiovascular disease. True for the LDL species overall. True especially for SD-LDL.

Step two: vegan diet lowers LDL. True on average.

Step three: therefore vegan diet protects from heart attack. Scientifically, you may not take this step. It is not proven. It is a bridge no one should have built.

Meta-analysis, k=96 studiesDinu et al., 2017. What vegetarians really do better

This large overview evaluated 86 cross-sectional studies and 10 prospective cohorts. Vegetarian diet lowers BMI, total cholesterol, LDL, and glucose. It is associated with about 25 percent less ischemic heart disease in observational data.

But for all-cause mortality, cancer mortality, and stroke incidence, no significant protection was shown. Protection for one component of risk, no benefit for the larger picture. That is the honest picture.

Dinu M, Abbate R, Gensini GF, Casini A, Sofi F. Vegetarian, vegan diets and multiple health outcomes. Crit Rev Food Sci Nutr. 2017;57(17):3640–3649. doi.org/10.1080/10408398.2016.1138447

Beyond that: plant-based diets can raise the share of SD-LDL, even when total LDL falls. They can deliver lectins, phytates, and oxalates that for some people can act inflammatorily. They can lead to deficiencies in B12, iron, zinc, and DHA, which are themselves cardiovascularly relevant. My own body felt this very clearly in three years vegan.

Reframe #4

Lowering a laboratory value is not proof of a longer life. The goal is not low cholesterol. The goal is intact endothelium. These two sentences sound similar. But they are completely different.

Part 7 · Meat, differentiated

Hundreds of thousands of studies on meat exist. None can say: “Meat is unhealthy.” Period.

Meat has been part of human nutrition for thousands of years. The statement “meat makes you sick” is at the level of observational studies not tenable. A large meta-analysis from 2019 showed very clearly that the evidence quality for the recommendation to eat less red meat is weak. If the same statistical procedure is applied to other foods, identical, equally non-specific statements emerge.

What does allow a statement is differentiation. Meat is not equal to meat. The following factors decide whether meat is associated with disease in a dataset:

What is often really behind “meat is unhealthy”
  • Husbandry and feeding. Animals from mass production fed soy and corn have an omega-6 to omega-3 ratio of about 15:1 or more. Pasture meat from a cow that ate grass sits at about 2:1.
  • Processing. Sausage, salami, hot dogs are not the same as a steak. Curing salts, nitrates, smoking processes generate other compounds that have their own effects.
  • Combination. Whoever eats meat with fries, beer, and cigarettes lives differently from someone eating pasture meat with vegetables and olive oil. Observational studies can rarely separate this cleanly.
  • Concomitant factors. People who eat lots of processed meat also tend, in many studies, to eat fewer vegetables, more sugar, more alcohol, are more often overweight, and move less. “Meat” is then a marker for an entire lifestyle.
  • Total calories and insulin resistance. Large caloric intake with insulinogenic effect creates the metabolic state in which the endothelium is chronically irritated.

My personal position: bad meat is bad. Good meat is good. The question is always: how much, combined with what, in what context, with what insulin resistance. When these factors are controlled, meat is generally not its own risk factor.

Fair counter-position

A large meta-analysis from 2022 (Zhao et al., Circulation) found that every additional daily egg portion of 50 g was associated with about 4 to 9 percent increased cardiovascular mortality. This is a serious observational study that I do not hide. But: observational studies are not causal. And the population studied in this meta-analysis was heterogeneous, with partly high shares of processed egg products and in different lifestyle contexts. The question remains: is it the egg or the lifestyle around it? The dispute is not yet decided.

Part 8 · Genetics and geography

We are not all alike. And that is exactly what makes every blanket dietary recommendation questionable.

The mitochondrial researcher Douglas Wallace has shown something exciting: our mitochondrial DNA has, depending on where our ancestors lived for thousands of years, adapted to the food available there.

Anyone with a family lineage from the far north tends to carry mitochondrial haplotypes that metabolize fat very efficiently. Inuit, Sami, and northern European lines show clear adaptations to fat-rich, low-carbohydrate nutrition over many generations.

Anyone from the equatorial belt tends to be better adapted to plant carbohydrates, because photosynthesis runs all year there and plants are available year-round.

Enzymatically too there is enormous variance. The pepsin activity in the stomach, which digests meat, can differ between two healthy people by a factor of 1,000. The biochemist Roger Williams documented this well in his classic Biochemical Individuality. Indigenous peoples like the Maasai consume huge amounts of animal fat, milk, and even blood, and show extraordinarily good metabolic health. Indigenous peoples like the Hadza eat lots of honey and plants. They too are metabolically healthy. Not one diet fits all.

There is no “the” healthy diet. There is only “your” healthy diet. And finding it out is work. But worthwhile work.
Part 9 · Fair differentiation

So you do not misunderstand me: LDL can be a causal factor. But not every LDL. And not at every age.

An honest cholesterol discussion has to show both sides. Here are the most important studies that challenge or differentiate my position.

EAS consensus, n>2 millionFerence et al., 2017, European Heart Journal. LDL is causal in ASCVD

This consensus statement of the European Atherosclerosis Society summarizes more than 200 cohort studies, Mendelian randomization studies, and randomized trials with over 2 million participants and over 150,000 events. The result: LDL has a causal effect on atherosclerotic cardiovascular disease, log-linearly dependent on level and duration.

That is the solid counter-position. It is real. What differentiation does allow: this consensus statement concerns the LDL species, not the individual person with phenotype A, good HDL, low triglycerides, and clean Apo-B. For that person, risk cannot be derived from the LDL number alone.

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38(32):2459–2472. doi.org/10.1093/eurheartj/ehx144

Systematic review, 19 cohorts, n=68,094Ravnskov et al., 2016, BMJ Open. In the elderly, LDL-C is often inversely associated with mortality

This systematic overview evaluated 19 cohort studies in people over 60. In 92 percent of the subjects studied, an inverse association was found between LDL cholesterol and all-cause mortality. Higher LDL went with longer life.

The authors’ conclusion: the cholesterol hypothesis is not tenable for the elderly. Routine LDL lowering in this age group should be reassessed. This result is virtually never heard in German GP practice.

Ravnskov U, Diamond DM, Hama R, et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly. BMJ Open. 2016;6(6):e010401. doi.org/10.1136/bmjopen-2015-010401

Prospective cohort, n=100, 1 yearSoto-Mota et al., 2025, JACC Advances. KETO-CTA: plaque predicts plaque, ApoB does not

100 metabolically healthy, lean people on a ketogenic diet with high LDL-C, high HDL, and low triglycerides, that is, the classic Lean Mass Hyper-Responder profile. One-year follow-up with coronary CT.

Result: neither baseline Apo-B nor cumulative LDL-C exposure correlated with plaque growth. What predicted plaque growth was the existing plaque itself. Bayes factor 6 to 10 for the null hypothesis versus the LDL hypothesis.

Important framing: small, highly selected population. It does not refute the EAS consensus statement. But it shows: there are subgroups in which the LDL-C model does not apply. Under keto, LDL can rise or fall without cardiovascular consequence.

Soto-Mota A, Norwitz NG, Manubolu VS, et al. Longitudinal Data From the KETO-CTA Study: Plaque Predicts Plaque, ApoB Does Not. JACC Adv. 2025;4(7):101686. doi.org/10.1016/j.jacadv.2025.101686

Interim summary

There is very strong evidence that LDL as a species contributes causally to atherosclerosis. There is also strong evidence that this does not apply equally to every person, in every age, in every metabolic context. Both must be allowed to be true at the same time. It is exactly this simultaneous truth that GPs currently rarely offer.

Part 10 · Statins

Statins work. And statins do not work. Both are true, depending on whom you give them to.

I am not generally against statins. In people with familial hypercholesterolemia, after a heart attack, with documented plaque and several risk factors, they are very probably an advantage. What I find problematic is the prescription as primary prevention in young, otherwise healthy people with isolated high LDL and an otherwise excellent profile. That is exactly what happens in Germany every day.

Meta-analysis, 62 RCTs, n=120,456Cai et al., 2021, BMJ. Statins in primary prevention

Cochrane-style meta-analysis. Real but moderate benefits in primary prevention. At the same time, increased risk for self-reported muscle complaints, liver dysfunction, kidney impairment, and eye problems. With low baseline risk, the absolute benefit is small.

Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention. BMJ. 2021;374:n1537. doi.org/10.1136/bmj.n1537

Meta-analysis, 13 RCTs, n=91,140Sattar et al., 2010, Lancet. Statins raise diabetes risk

9 percent increased risk of new-onset diabetes under statins, in absolute terms one additional diabetes case per 255 people over four years. In high-risk patients, the protection from heart attack outweighs this. In young, otherwise healthy people, it has to be weighed differently. Diabetes is itself a massive cardiovascular risk factor.

Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes. Lancet. 2010;375(9716):735–742. doi.org/10.1016/S0140-6736(09)61965-6

Mechanism reviewOkuyama et al., 2015. Statins as mitochondrial toxins

Statins inhibit not only cholesterol synthesis but also the body’s own production of coenzyme Q10 and heme A, both essential for ATP formation in mitochondria. They also inhibit the synthesis of vitamin K2, which protects arteries from calcification, and the formation of selenium-containing proteins like glutathione peroxidase. The authors argue that the paradoxical increase in heart failure and arterial calcification despite cholesterol lowering could also be explained by precisely these off-target effects.

Statins interfere in over 700 cellular reactions. This is contested and not finally proven. It is, however, pharmacologically plausible and scientifically published.

Okuyama H, Langsjoen PH, Hamazaki T, et al. Statins Stimulate Atherosclerosis and Heart Failure: Pharmacological Mechanisms. Expert Rev Clin Pharmacol. 2015;8(2):189–199. doi.org/10.1586/17512433.2015.1011125

What you should know

Until the early 2000s, pharmaceutical companies were not obliged to publish all study results. Negative results often stayed in the drawer. Only since 2005 have leading journals required pre-registration of clinical trials. This created a bias whose full extent we are still working through. The first major statin studies of the 1990s and early 2000s fell exactly in this period.

And this also belongs to the truth: if you have been to a cardiologist and they recommend statins, that does not automatically mean they have looked at your values in differentiated detail. Their primary task is to apply German guidelines. These guidelines do not necessarily call for statins in pure primary prevention at low risk. They are still often prescribed.

Reframe #5

Do not ask your physician: “How much does this pill lower my LDL?” Ask: “How much does this pill lower my absolute risk of having a heart attack in the next ten years?” That is a different number. A much smaller number. It is the number that really matters.

Part 11 · How I test

What a modern cardiovascular risk profile looks like.

When someone comes to me with the question “am I cardiovascularly at risk?”, I do not look at total cholesterol. I look at the whole profile. I do this very thoroughly, because I look at the whole topic in scientifically differentiated enough detail to arrive at different truths from people who treat with science from 1950.

What can be checked in a differentiated cholesterol diagnostic
  • Apo-B as a measure of the number of atherogenic particles
  • Lp(a) at least once in a lifetime, because it is genetic
  • LDL including subclasses, that is phenotype A or B (SD-LDL, MD-LDL, LD-LDL)
  • HDL and HDL subclasses, because high HDL values allow more LDL before risk rises
  • Triglycerides and the triglyceride-to-HDL ratio as insulin resistance markers
  • Fasting insulin and HOMA-IR
  • HbA1c
  • hsCRP as an unspecific inflammation marker
  • Homocysteine, vitamin B12, folate, and vitamin D
  • Waist circumference, blood pressure, sleep quality, HRV
  • oxLDL and Omega-3 Index
  • If suspected: coronary calcium score (CAC) as imaging risk assessment

That sounds elaborate. It is elaborate. But it is the only way to really see what is going on in your circulation. One number is not enough. One value alone is not enough. A statin recommendation based on total cholesterol alone is medicine from 1955.

True freedom

You do not have to choose between eggs and your heart. That choice was never cleanly put to you.

If this article should accomplish one single thing, it is this: to free you from the wrong question.

The wrong question runs “Do I take butter or margarine today? Eggs or oats?”

The right question runs: “What pulls my endothelium out of balance every day? Where are the real stressors? Which can I influence?”

Energy, clarity, years of life. Those are the real values. Not a lowered LDL value on a lab slip.

This freedom is what I found for myself. My beard grows, my nails are without white spots, my energy is balanced, my sleep quality is good. I eat meat, I eat eggs, I avoid seed oils, I take care of my insulin sensitivity. And I regularly measure the right values. Apo-B. Lp(a). Triglycerides. Fasting insulin. HbA1c. That is how I know how my endothelium is really doing.

Concrete levers

Three things you can do this week.

First, out with the industrial seed oils. Sunflower, safflower, soy, corn, canola. Look in your cupboard. Look at the ingredient list of your favorite snacks. You will be amazed where linoleic acid hides. Replace with extra virgin olive oil, butter, ghee, tallow, or coconut oil.

Second, have the right values measured next time. Apo-B. Lp(a) once. Triglycerides. Fasting insulin. HbA1c. If your GP does not run these, you can ask a holistically oriented physician or a specialized lab. Not every health insurer covers it. But it can bring much more clarity than twenty years of total cholesterol observation.

Third, focus on insulin resistance. Fast carbohydrates out, especially after 6 pm. Movement into daily life, ideally before or right after meals. Sleep from 10 pm to 6 am in the dark hours. Stress hygiene in the evening. These four levers alone can substantially improve your metabolic profile.

If you do not just want to read but really understand where your own cardiovascular risk lies, you can book an appointment below this article. We will go through your values together. With the differentiated view this topic deserves.

Sources

Re-analyses of historical RCTs

Ramsden CE, Zamora D, Leelarthaepin B, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death. BMJ. 2013;346:e8707. doi.org/10.1136/bmj.e8707 [RCT reanalysis, n=458, secondary prevention]

Ramsden CE, Zamora D, Majchrzak-Hong S, et al. Re-evaluation of the traditional diet-heart hypothesis: Minnesota Coronary Experiment (1968–73). BMJ. 2016;353:i1246. doi.org/10.1136/bmj.i1246 [RCT reanalysis + meta-analysis, n=9,423]

LDL subclasses, Apo-B, Lp(a)

Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis. 1996;124 Suppl:S1–9. doi.org/10.1016/0021-9150(96)05851-0 [Framingham overview]

Vekic J, Zeljkovic A, Cicero AFG, et al. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. Medicina (Kaunas). 2022;58(2):299. doi.org/10.3390/medicina58020299 [Review]

Vekic J, Zeljkovic A, Al Rasadi K, et al. A New Look at Novel Cardiovascular Risk Biomarkers. Metabolites. 2022;12(2):108. doi.org/10.3390/metabo12020108 [Review]

Sniderman A, Kwiterovich PO. Update on the detection and treatment of atherogenic low-density lipoproteins. Curr Opin Endocrinol Diabetes Obes. 2013;20(2):140–147. doi.org/10.1097/MED.0b013e32835ed9cb [Review, Apo-B vs cholesterol markers]

Kamstrup PR. Lipoprotein(a) and Cardiovascular Disease. Clin Chem. 2021;67(1):154–166. doi.org/10.1093/clinchem/hvaa247 [Review, Mendelian randomization]

Griffin BA. Lipoprotein Atherogenicity: An Overview of Current Mechanisms. Proc Nutr Soc. 1999;58(1):163–169. doi.org/10.1079/pns19990022 [Review]

Hirano T. Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb. 2018;25(9):771–782. doi.org/10.5551/jat.RV17023 [Review]

Consensus and guidelines

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. EAS Consensus. Eur Heart J. 2017;38(32):2459–2472. doi.org/10.1093/eurheartj/ehx144 [EAS consensus, >2 million participants]

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188. doi.org/10.1093/eurheartj/ehz455 [Guideline]

Counter-position to LDL as universal risk

Ravnskov U, Diamond DM, Hama R, et al. Lack of an association or an inverse association between LDL-C and mortality in the elderly. BMJ Open. 2016;6(6):e010401. doi.org/10.1136/bmjopen-2015-010401 [Systematic review, n=68,094]

Soto-Mota A, Norwitz NG, Manubolu VS, et al. KETO-CTA: Plaque Predicts Plaque, ApoB Does Not. JACC Adv. 2025;4(7):101686. doi.org/10.1016/j.jacadv.2025.101686 [Prospective cohort, n=100]

Norwitz NG, Mindrum MR, Giral P, et al. Elevated LDL-cholesterol levels among lean mass hyper-responders. J Clin Lipidol. 2022;16(6):765–768. doi.org/10.1016/j.jacl.2022.10.010 [Editorial, LMHR]

Janič M, Lunder M, Janež A, et al. Rosuvastatin Improved LDL Subfractions Profile in a Patient with Type 1 Diabetes Following a Ketogenic Diet. Curr Vasc Pharmacol. 2025. doi.org/10.2174/0115701611370578250621183337 [Case report]

Fatty acids and endothelium

DiNicolantonio JJ, O’Keefe JH. Omega-6 vegetable oils as a driver of coronary heart disease: the oxidized linoleic acid hypothesis. Open Heart. 2018;5(2):e000898. doi.org/10.1136/openhrt-2018-000898 [Mechanism review]

Reaven P, Parthasarathy S, Grasse BJ, et al. Effects of Oleate-Rich and Linoleate-Rich Diets on the Susceptibility of Low Density Lipoprotein to Oxidative Modification. J Clin Invest. 1993;91(2):668–676. doi.org/10.1172/JCI116247 [Human study]

Berry EM, Eisenberg S, Haratz D, et al. Jerusalem Nutrition Study. Am J Clin Nutr. 1991;53(4):899–907. doi.org/10.1093/ajcn/53.4.899 [RCT, crossover]

Afonso MS, Castilho G, Lavrador MS, et al. The impact of dietary fatty acids on macrophage cholesterol homeostasis. J Nutr Biochem. 2014;25(2):95–103. doi.org/10.1016/j.jnutbio.2013.10.001 [Review, mechanism]

Statins

Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention. BMJ. 2021;374:n1537. doi.org/10.1136/bmj.n1537 [Meta-analysis, 62 RCTs, n=120,456]

Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes. Lancet. 2010;375(9716):735–742. doi.org/10.1016/S0140-6736(09)61965-6 [Meta-analysis, 13 RCTs, n=91,140]

Okuyama H, Langsjoen PH, Hamazaki T, et al. Statins Stimulate Atherosclerosis and Heart Failure. Expert Rev Clin Pharmacol. 2015;8(2):189–199. doi.org/10.1586/17512433.2015.1011125 [Mechanism review]

Nutritional factors

Dinu M, Abbate R, Gensini GF, Casini A, Sofi F. Vegetarian, vegan diets and multiple health outcomes. Crit Rev Food Sci Nutr. 2017;57(17):3640–3649. doi.org/10.1080/10408398.2016.1138447 [Meta-analysis, k=96 studies]

Zhao B, Gan L, Graubard BI, et al. Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Mortality. Circulation. 2022;145(20):1506–1520. doi.org/10.1161/CIRCULATIONAHA.121.057642 [Meta-analysis, n=3,601,401, counter-position]

Note on methodology. This article follows the differentiated model of modern lipidology. It presents both the mainstream position of the EAS and ESC and differentiating studies. Statements on effect, risk, and outcomes are to be understood as pointers to mechanisms and possible relationships, not as health promises. Therapeutic decisions, especially regarding statins, belong in the hands of a medical professional who knows your values, your family history, and your life situation. Where a section rests on few, partly conflicting studies, I note this in the text. Making this uncertainty transparent is part of serious science communication.

Have questions or want to book an appointment?

We'd be happy to advise you personally at our practice.

Book appointment